1. Home
  2. CNSP vs PPCB Comparison

CNSP vs PPCB Comparison

Compare CNSP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

N/A

Current Price

$2.35

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

PPCB

Propanc Biopharma Inc.

HOLD

Current Price

$0.11

Market Cap

1.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNSP
PPCB
Founded
2017
2007
Country
United States
Australia
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
1.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CNSP
PPCB
Price
$2.35
$0.11
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
31.4K
6.3M
Earning Date
05-15-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
8.03
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.10
52 Week High
$10.59
$10.69

Technical Indicators

Market Signals
Indicator
CNSP
PPCB
Relative Strength Index (RSI) 42.59 42.85
Support Level $2.06 N/A
Resistance Level $2.95 $0.13
Average True Range (ATR) 0.28 0.02
MACD 0.04 0.00
Stochastic Oscillator 45.46 17.23

Price Performance

Historical Comparison
CNSP
PPCB

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: